INTRA-CELLULAR THERAPIES INC (ITCI) Stock Income Statement
NASDAQ:ITCI - Nasdaq - US46116X1019 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 680.85M | 464.37M | 250.30M | 83.80M | 22.80M | |||
| Cost Of Goods | 56.96M | 33.74M | 20.40M | 8.00M | 1.90M | |||
| Gross Profit | 623.89M | 430.63M | 229.90M | 75.80M | 20.90M | |||
| Operating Expenses | 740.61M | 590.01M | 493.50M | 361.50M | 252.10M | |||
| Research and Development | 236.12M | 180.14M | 134.70M | 88.80M | 65.80M | |||
| Selling, General, and Administrative Expenses | 504.49M | 409.86M | 358.80M | 272.60M | 186.40M | |||
| Operating Income | -116.72M | -159.38M | -263.60M | -285.70M | -231.20M | |||
| Interest Income/Expense | 42.52M | 20.34M | 7.40M | 1.60M | 4.20M | |||
| Income Before Taxes | -74.20M | -139.04M | -256.30M | -284.10M | -227.00M | |||
| Income Tax | 473.00K | 636.00K | 0.00 | 0.00 | 0.00 | |||
| Net Income | -74.68M | -139.67M | -256.30M | -284.10M | -227.00M | |||
| EBITDA | -116.21M | -158.85M | -262.94M | -285.17M | -230.67M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.72 | -1.46 | -2.72 | -3.50 | -3.23 | |||
| Non GAAP EPS | -0.73 | -1.46 | -2.72 | -3.50 | -3.24 | |||
| Statistics | ||||||||
| Gross Profit Margin | 91.63% | 92.73% | 91.85% | 90.45% | 91.67% | |||
| Profit Margin | -10.97% | -30.08% | -102.40% | -339.02% | -995.61% | |||
| Operating Profit Margin | -17.14% | -34.32% | -105.31% | -340.93% | -1014.04% | |||
All data in USD